Trial Profile
Single-Arm, Phase II of Immunotherapy With Pembrolizumab for the Prevention of Lung Cancer (IMPRINT-Lung)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 Feb 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms IMPRINT-Lung
- 14 Nov 2023 Number of treatment arms decreased from 2 to 1 by the removal of Active Comparator arm. Biospecimen Collection procedure is added to the treatments.
- 14 Nov 2023 Planned number of patients changed from 81 to 48.
- 05 Sep 2023 Planned End Date changed from 31 Dec 2024 to 31 Jul 2024.